四价脑膜炎球菌疫苗MenACWY-TT单独或与13价肺炎球菌结合疫苗联合接种于幼儿的1剂或2剂免疫原性与安全性:一项III期开放标签随机研究
这项III期开放标签多中心随机研究(NCT01939158)纳入802名12-14月龄健康幼儿,随机分为4组:1剂MenACWY-TT、2剂MenACWY-TT、MenACWY-TT与PCV13联合接种、PCV13后序贯MenACWY-TT。结果显示MenACWY-TT单剂即具免疫原性,第二剂可提高针对MenW和MenY的hSBA应答,且与PCV13联合接种不损害任一疫苗的免疫原性或安全性。
要点
- MenACWY-TT单剂接种后,≥92.8%幼儿rSBA滴度≥1:8,≥62.5%幼儿hSBA滴度≥1:4(各血清群)。
- 接种2剂后,rSBA≥1:8者≥98.0%,hSBA≥1:4者≥95.3%;MenW和MenY的hSBA≥1:4比例高于单剂组。
- MenACWY-TT与PCV13联合接种对免疫应答非劣于分开接种,不良事件发生率组间相当。
核心结论
- MenACWY-TT在12-14月龄幼儿中单剂接种即具备免疫原性,第二剂可增强针对MenW和MenY的hSBA应答。
- MenACWY-TT与PCV13可联合接种,不损害任一疫苗的免疫原性或安全性。
研究设计与样本
- III期、开放标签、对照、多中心研究(NCT01939158),纳入802名12-14月龄健康幼儿。
- 随机分为4组:M0接种1剂MenACWY-TT(ACWY_1组)、M0和M2各接种1剂MenACWY-TT(ACWY_2组)、M0联合接种MenACWY-TT和PCV13(Co-ad组)、M0接种PCV13后M2接种MenACWY-TT(PCV13/ACWY组)。
- 每次接种后1个月评估免疫应答;主动和被动症状分别于每次接种后4天和31天内记录;严重不良事件(SAE)和新发慢性病(NOCI)记录至首剂接种后M9。
主要发现
- MenACWY-TT首剂后,各血清群rSBA滴度≥1:8的幼儿比例≥92.8%,hSBA滴度≥1:4的比例≥62.5%。
- MenACWY-TT第二剂后,rSBA滴度≥1:8的比例≥98.0%,hSBA滴度≥1:4的比例≥95.3%。
- 2剂较1剂MenACWY-TT的hSBA滴度≥1:4比例更高:MenW为97.1% vs 62.5-68.9%,MenY为95.3% vs 64.3-67.6%。
- 联合接种MenACWY-TT与PCV13的免疫应答非劣于分开接种。
- ACWY_1、ACWY_2、Co-ad和PCV13/ACWY组的SAE发生率分别为4.9%、5.1%、5.5%和7.5%,NOCI发生率分别为2.0%、3.0%、0.5%和3.5%;3名幼儿报告的4例SAE与疫苗相关;报告2例与疫苗无关的致死性SAE。
关键数值与推荐
- 免疫原性主要指标:rSBA滴度≥1:8和hSBA滴度≥1:4的幼儿比例。
- 联合接种非劣效性:与分开接种相比,联合接种MenACWY-TT和PCV13的免疫应答达到非劣效。
- 安全性指标:主动和被动症状、SAE及NOCI的发生率。
临床怎么用
- 原文结论指出MenACWY-TT在12-14月龄幼儿中单剂接种具免疫原性,第二剂可增强对MenW和MenY的hSBA应答。
- 原文结论指出MenACWY-TT和PCV13可联合接种而不损害任一疫苗的免疫原性或安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the immunogenicity and safety of 1 and 2 doses of quadrivalent meningococcal serogroup A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT) given alone or co-administered with 13-valent pneumococcal conjugate vaccine (PCV13) in toddlers. METHODS: In this phase III, open-label, controlled, multicentre study (NCT01939158), healthy toddlers aged 12-14 months were randomised into 4 groups to receive 1 dose of MenACWY-TT at month (M) 0 (ACWY_1), 2 doses of MenACWY-TT at M0 and M2 (ACWY_2), MenACWY-TT and PCV13 at M0 (Co-ad), or PCV13 at M0 and MenACWY-TT at M2 (PCV13/ACWY). Immune responses were assessed 1 month post-each vaccination. Solicited and unsolicited symptoms were recorded for 4 and 31 days post-each vaccination, respectively; serious adverse events (SAEs) and new onset of chronic illnesses (NOCIs) up to M9 from first vaccination. RESULTS: 802 toddlers were vaccinated. Post-dose 1 of MenACWY-TT, ≥92.8% of toddlers had rSBA titres ≥1:8, and ≥62.5% had hSBA titres ≥1:4 for each meningococcal serogroup. Post-dose 2 of MenACWY-TT, rSBA titres ≥1:8 were observed in ≥98.0% and hSBA titres ≥1:4 in ≥95.3% of toddlers. Percentages of toddlers with hSBA titres ≥1:4 were higher after 2 doses versus 1 dose of MenACWY-TT for MenW (97.1% versus 62.5-68.9%) and MenY (95.3% versus 64.3-67.6%). Non-inferiority of immune responses to co-administered MenACWY-TT and PCV13 over their separate administration was demonstrated. AEs incidence was comparable among groups. SAEs were reported for 4.9%, 5.1%, 5.5% and 7.5%, and NOCIs for 2.0%, 3.0%, 0.5% and 3.5% of toddlers in the ACWY_1, ACWY_2, Co-ad and PCV13/ACWY groups, respectively; 4 SAEs reported in 3 toddlers were vaccine-related. Two fatal vaccine-unrelated SAEs were reported. CONCLUSION: MenACWY-TT was immunogenic when administered as a single dose at 12-14 months of age. A second dose in toddlers increased hSBA responses against MenW and MenY. MenACWY-TT and PCV13 can be co-administered without impairing the immunogenicity or safety profile of either vaccine.
引用
- Cutland CL, Nolan T, Halperin SA, et al. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine. 2018. PMID: 29503112. doi:10.1016/j.vaccine.2018.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。